Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp. | ANAVEX 2-73 - (U.S. RS-001) | Rett syndrome | Phase 2 | Data Released | Oral | Genetic Disorder |
| Anavex Life Sciences Corp. | ANAVEX 2-73-RS-003 - (EXCELLENCE) | Pediatric Rett Syndrome | Phase 2/3 | Data Released | Oral | Genetic Disorder |
| ANI Pharmaceuticals Inc. | Cortrophin Gel | Acute Gout Flares | Phase 3 | Enrollment Initiation | Intramuscular or subcutaneous | Non-Opioid Analgesic |
| Anika Therapeutics Inc. | Cingal | Osteoarthritis of the knee | Phase 3 | Trial Completed | Intra-articular | Orthopedic |
| Anika Therapeutics Inc. | Cingal | Osteoarthritis of the knee | Phase 3 | Trial Completed | Intra-articular | Orthopedic |
| Anika Therapeutics Inc. | HYALOFAST - (FastTRACK) | Cartilage defects of the knee | Phase 3 | Ongoing | Intra-articular | Orthopedic |
| Anika Therapeutics Inc. | HYALOFAST - (FastTRACK) | Cartilage defects of the knee | Phase 3 | Ongoing | Intra-articular | Orthopedic |
| Annexon Inc. | Tanruprubart (ANX005) | Guillain-Barré Syndrome (GBS) | BLA Filing | Data Released | Intravenous | Neurology |
